Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial

Amit Bar-Or[1], Xavier Montalban[2], Xixi Hu[3], Harald Kropshofer[4], Petra Kukkaro[4], Neva Coello[4], Inga Ludwig[4], Roman Willi[4], Martin Zalesak[4], Krishnan Ramanathan[4], Bernd C. Kieseier[4,5], Dieter A. Häring[4], Morten Bagger[4], Edward Fox[6]

[1]Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; [2]Department of Neurology-Neuroimmunology and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain; [3]Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; [4]Novartis Pharma AG, Basel, Switzerland; [5]Department of Neurology, Medical Faculty, Heinrich-Heine University, Dusseldorf, Germany; [6]Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock, Austin, Texas, USA

Corresponding Author:

Dr. Amit Bar-Or

Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Email: amitbar@pennmedicine.upenn.edu

Supplementary Material: Adjusted Geometric Mean sNfL Levels Over Time



OMB, ofatumumab; sc, subcutaneous.